KR100907938B1 - 발기 기능장애의 치료를 위한 알카노일 ｌ-카르니틴의 용도 - Google Patents

발기 기능장애의 치료를 위한 알카노일 ｌ-카르니틴의 용도 Download PDF

Info

Publication number
KR100907938B1
KR100907938B1 KR1020047007882A KR20047007882A KR100907938B1 KR 100907938 B1 KR100907938 B1 KR 100907938B1 KR 1020047007882 A KR1020047007882 A KR 1020047007882A KR 20047007882 A KR20047007882 A KR 20047007882A KR 100907938 B1 KR100907938 B1 KR 100907938B1
Authority
KR
South Korea
Prior art keywords
acid
erectile dysfunction
carnitine
treatment
alkanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047007882A
Other languages
English (en)
Korean (ko)
Other versions
KR20050044594A (ko
Inventor
알레아르도 코베레크
안드레아 렌지
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20050044594A publication Critical patent/KR20050044594A/ko
Application granted granted Critical
Publication of KR100907938B1 publication Critical patent/KR100907938B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020047007882A 2001-12-04 2002-12-04 발기 기능장애의 치료를 위한 알카노일 ｌ-카르니틴의 용도 Expired - Fee Related KR100907938B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2001A000708 2001-12-04
IT2001RM000708A ITRM20010708A1 (it) 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
PCT/IT2002/000758 WO2003047563A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
KR20050044594A KR20050044594A (ko) 2005-05-12
KR100907938B1 true KR100907938B1 (ko) 2009-07-16

Family

ID=11455907

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047007882A Expired - Fee Related KR100907938B1 (ko) 2001-12-04 2002-12-04 발기 기능장애의 치료를 위한 알카노일 ｌ-카르니틴의 용도

Country Status (16)

Country Link
US (3) US20050080018A1 (enExample)
EP (1) EP1450782B9 (enExample)
JP (1) JP4370169B2 (enExample)
KR (1) KR100907938B1 (enExample)
AT (1) ATE309800T1 (enExample)
AU (1) AU2002365847A1 (enExample)
CA (1) CA2465471C (enExample)
DE (1) DE60207442T2 (enExample)
DK (1) DK1450782T3 (enExample)
ES (1) ES2250749T3 (enExample)
HU (1) HU229214B1 (enExample)
IT (1) ITRM20010708A1 (enExample)
MX (1) MXPA04005269A (enExample)
PL (1) PL211211B1 (enExample)
SI (1) SI1450782T1 (enExample)
WO (1) WO2003047563A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040561A1 (it) * 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
IT1397867B1 (it) * 2010-02-03 2013-02-04 Brotzu Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
JP2016520564A (ja) 2013-04-18 2016-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
WO2016174155A1 (en) * 2015-04-30 2016-11-03 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003364A1 (en) * 1997-07-16 1999-01-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Nutritional composition for subjects under stress
WO2001026666A2 (en) * 1999-10-08 2001-04-19 Sigma-Tau Healthscience S.P.A. Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
DK0793962T3 (da) * 1996-03-04 2000-05-22 Sigma Tau Ind Farmaceuti Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6241471B1 (en) * 1999-08-26 2001-06-05 General Electric Co. Turbine bucket tip shroud reinforcement

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003364A1 (en) * 1997-07-16 1999-01-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Nutritional composition for subjects under stress
WO2001026666A2 (en) * 1999-10-08 2001-04-19 Sigma-Tau Healthscience S.P.A. Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Acta Urol Ital., 10(3), 186-187, 1996

Also Published As

Publication number Publication date
EP1450782B9 (en) 2006-05-17
ES2250749T3 (es) 2006-04-16
HUP0402062A2 (hu) 2005-02-28
JP2005511655A (ja) 2005-04-28
ATE309800T1 (de) 2005-12-15
DE60207442D1 (de) 2005-12-22
US20120041005A1 (en) 2012-02-16
ITRM20010708A1 (it) 2003-06-04
US20070117762A1 (en) 2007-05-24
WO2003047563A1 (en) 2003-06-12
EP1450782B1 (en) 2005-11-16
CA2465471A1 (en) 2003-06-12
CA2465471C (en) 2010-10-19
HUP0402062A3 (en) 2012-09-28
KR20050044594A (ko) 2005-05-12
DK1450782T3 (da) 2006-02-20
PL211211B1 (pl) 2012-04-30
US8343979B2 (en) 2013-01-01
DE60207442T2 (de) 2006-07-27
HU229214B1 (hu) 2013-09-30
EP1450782A1 (en) 2004-09-01
ITRM20010708A0 (it) 2001-12-04
SI1450782T1 (sl) 2006-02-28
PL371131A1 (en) 2005-06-13
US20050080018A1 (en) 2005-04-14
MXPA04005269A (es) 2004-10-11
AU2002365847A1 (en) 2003-06-17
JP4370169B2 (ja) 2009-11-25

Similar Documents

Publication Publication Date Title
US8343979B2 (en) Use of alkanoyl L-carnitine for the treatment of erectile dysfunction
JP5690261B2 (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも１つのアミノ酸を含む組成物および使用法
CA1323572C (en) Doxazosin as an anti-atherosclerosis agent
TWI513462B (zh) 糖尿病之治療或預防藥
JPH0337525B2 (enExample)
KR100244092B1 (ko) L-카르니틴 또는 아실l-카르니틴과 ace-억제제를 함유한 심장혈관질환치료용 약제조성물과 그 치료방법
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
CN101087602B (zh) L-肉碱和葡萄糖治疗心血管疾病的应用
JPH02262519A (ja) 糖尿病性神経障害治療剤
JP2004505919A (ja) 一次性頭痛の処置におけるビタミン配合物の使用
US20070087975A1 (en) Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
KR20070085961A (ko) 발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도
CHATTERJEE NEW INOTROPIC AGENTS CHARLES A. SIMONTONl
HK1113542B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1166003B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20130625

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20140625

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20150624

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20160627

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20170628

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20180627

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20190627

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200709

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200709